US 12,275,715 B2
Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
Jian Lin, Acton, MA (US); Anna Ericsson, Shrewsbury, MA (US); Ann-Marie Campbell, Monroe, CT (US); Gary Gustafson, Ridgefield, CT (US); Zhongguo Wang, Lexington, MA (US); R. Bruce Diebold, Waltham, MA (US); Susan Ashwell, Carlisle, MA (US); David R. Lancia, Jr., Boston, MA (US); Justin Andrew Caravella, Cambridge, MA (US); and Wei Lu, Newton, MA (US)
Assigned to FORMA Therapeutics, Inc., Watertown, MA (US)
Filed by FORMA Therapeutics, Inc., Watertown, MA (US)
Filed on Nov. 9, 2023, as Appl. No. 18/506,060.
Application 18/506,060 is a continuation of application No. 17/984,069, filed on Nov. 9, 2022, abandoned.
Application 17/984,069 is a continuation of application No. 17/101,018, filed on Nov. 23, 2020, granted, now 11,498,913, issued on Nov. 15, 2022.
Application 17/101,018 is a continuation of application No. 16/712,951, filed on Dec. 12, 2019, granted, now 10,889,567, issued on Jan. 12, 2021.
Application 16/712,951 is a continuation of application No. 16/290,240, filed on Mar. 1, 2019, granted, now 10,550,098, issued on Feb. 4, 2020.
Application 16/290,240 is a continuation of application No. 15/964,844, filed on Apr. 27, 2018, granted, now 10,414,752, issued on Sep. 17, 2019.
Application 15/964,844 is a continuation of application No. 15/452,256, filed on Mar. 7, 2017, abandoned.
Application 15/452,256 is a continuation of application No. 14/858,167, filed on Sep. 18, 2015, granted, now 9,834,539, issued on Dec. 5, 2017.
Claims priority of provisional application 62/150,812, filed on Apr. 21, 2015.
Claims priority of provisional application 62/128,089, filed on Mar. 4, 2015.
Claims priority of provisional application 62/053,006, filed on Sep. 19, 2014.
Prior Publication US 2024/0150319 A1, May 9, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 401/12 (2006.01); A61P 35/00 (2006.01); C07D 401/14 (2006.01); C07D 471/04 (2006.01); A61K 31/47 (2006.01)
CPC C07D 401/12 (2013.01) [A61P 35/00 (2018.01); C07D 401/14 (2013.01); C07D 471/04 (2013.01); A61K 31/47 (2013.01)] 23 Claims
 
1. A compound of Formula I:

OG Complex Work Unit Chemistry
or pharmaceutical salt thereof,
wherein:
each W1 and W2 is independently CH, CF or N;
W3 is independently, CR2 or N;
U is N or CR6;
A is selected from the group consisting of H, D, halogen, CN, —CHO, —COOH, —COOR, —C(O)NH2, —C(O)NHR, R′S(O)2—, —O(CH2)nC(O)R′, R′S(O)—, heteroaryl, —SOMe, —SO2Me,

OG Complex Work Unit Chemistry
wherein X and Y are independently in each occurrence C, N, NR′, S, and O, provided that the ring containing X and Y cannot have more than 4 N or NH atoms or more than one S or O atoms, and wherein the S and O are not contiguous;
R and R′ at each occurrence are independently selected from the group consisting of H, OH, CN, —CH2CN, halogen, —NR7R8, CHCF2, CF3, C1-C6 alkyl, R7S(O)2—, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkylalkyl, 3- to 8-membered heterocyclyl, aryl, and heteroaryl, wherein each R and R′ are optionally substituted with one or more substituents selected from the group consisting of OH, halogen, C1-C6 alkoxy, NH2, R7S(O)2—, CN, C3-C8 cycloalkyl, 3- to 8-membered heterocyclyl, aryl, heteroaryl, and R7S(O)—;
R1 is independently OH, CN, halogen, CHCF2, CF3, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkenyl, C3-C8 cycloalkyl, 3- to 8-membered heterocyclyl, aryl, or heteroaryl, wherein each C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, 3- to 8-membered heterocyclyl, aryl, or heteroaryl is optionally substituted one or more times with substituents selected from the group consisting of halogen, OH, NH2, CN, C1-C6 alkyl, and C1-C6 alkoxy;
each R2 is independently H, OH, CN, halogen, CF3, CHF2, benzyl, C1-C6 alkyl, C1-C6 alkoxy, NH2, —O(CH2)nR′, —O(CH2)nC(O)NHR′, —O(CH2)nC(O)R′, NHR7, —N(R7)(R8), NHC(O)R7, NHS(O)R7, NHS(O)2R7, NHC(O)OR7, NHC(O)NHR7, —S(O)2NHR7, NHC(O)N(R8)R7, OCH2R7, CHRR′ or OCHR′R7, wherein C1-C6 alkyl, C1-C6 alkoxy is optionally substituted with one or more substituents selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl substituted with one or more halogen, 3- to 8-membered heterocyclyl, aryl, -heteroaryl-C(O)NH2, and heteroaryl;
or R1 and R2 can combine to form a C4-C6 cycloalkyl or a 3- to 8-membered heterocyclyl containing at least one atom selected from the group consisting of N, O, and S;
R3 is H, C1-C6 alkyl, or —OH;
R4 and R5 are independently H, halogen, CH2OH, C1-C3 alkyl, or C1-C3 alkyl substituted with halogen, or R4 and R5 when combined can form a C3-C6 cycloalkyl or C3-C6 heterocyclyl;
each R6 is H, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkoxy substituted with one or more halogen, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, 3- to 8-membered heterocyclyl, aryl, or heteroaryl, or C1-C6 alkyl substituted with one or more of halogen, oxo, or C1-C6 alkoxy;
R7 and R8 are independently H, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, 3- to 8-membered heterocyclyl, aryl, and heteroaryl; or when combined R7 and R8 can form a 3- to 8-membered heterocyclyl or heteroaryl ring, wherein each of R7 and R8 are optionally substituted with halogen;
R9 is independently H, D, CD3, CF3, C1-C6 alkyl, C2-6 alkenyl, C3-6 alkynyl, C3-C8 cycloalkyl, wherein the alkyl, alkenyl, alkynyl, and cycloalkyl is optionally substituted with amino, OH, halo, or alkoxy;
n is 0, 1, or 2; and
r is 0, 1, or 2;
with the proviso that when A is H, then R1 is not C1-C6 alkyl or C1-C6 alkoxy and R1 and R2 cannot combine to form a 3- to 8-membered heterocyclyl.